The ad hoc All United for MG coalition has established European Myasthenia Gravis Day — set for June 2 — to raise awareness of the neuromuscular autoimmune disease, and to call attention to the needs of this community of patients in Europe. The day will fall at the start of…
News
Thymus removal surgery is generally safe for the majority of elderly people who have myasthenia gravis (MG), a study in China found. In fact, all patients ages 65 and older in the study were safely discharged and did not need to stay longer in the hospital. Nonetheless, according to…
Early detection and treatment of a myasthenic crisis — a serious complication of myasthenia gravis (MG) — in a woman under general anesthesia avoided potentially life-threatening complications, according to a recent case report. The woman did not inform the anesthesiologist of her generalized MG, and she requested anesthesia…
Post-operative myasthenic crisis is a dangerous complication after thymus removal surgery for people with myasthenia gravis (MG) who had no tumor in their thymus, according to researchers who set out to identify factors that increase this risk in a recent study. They determined risk factors to be: having a…
Early and aggressive treatments tend to lead to better control of myasthenia gravis (MG) symptoms, a recent study reports. The study suggests MG patients given early treatment with high doses of the corticosteroid methylprednisolone directly into the bloodstream are more likely to have minimal disease manifestations. “The data presented…
Being male, requiring intubation, and receiving plasma exchange therapy were identified as the main predictors of longer hospital stays following an acute episode of disease worsening in people with myasthenia gravis (MG), according to a recent study. Data also show that patients who underwent surgery to remove the…
Sanofi is stopping the clinical development of tolebrutinib for treating myasthenia gravis (MG), the company announced in a recent press release. The decision was made after “careful evaluation of the emerging competitive treatment landscape in MG,” according to Sanofi, and will result in discontinuing the Phase…
Patient dosing has begun in the first placebo-controlled clinical trial evaluating Cartesian Therapeutics’ Descartes-08, an investigational CAR T-cell therapy for people with generalized myasthenia gravis (gMG). The Phase 2b randomized controlled trial (RCT), to include up to 30 adults with gMG, follows a crossover design, in which participants…
The Myasthenia Gravis Foundation of America (MGFA) has partnered with Alira Health to relaunch a patient registry for people with myasthenia gravis (MG) that “capitalizes on technological advances,” the nonprofit announced. The initial registry was launched in 2013. The rebranded MGFA Global MG Patient Registry is…
MuSK-CAART, an investigational cell-based therapy being developed to treat myasthenia gravis (MG) patients with anti-MuSK antibodies, eliminated disease-driving B-cells in a mouse model of the disease, a study showed. The findings, some of which were reported previously at a scientific conference, supported Cabaletta Bio’s request for a…
Recent Posts
- My twin loves junk food, but a veggie and fruit diet is helping him combat MG
- My secret book of survival in life with myasthenia gravis
- MG symptoms in US strike earlier and harder depending on race and ethnicity
- FDA grants priority review for expanded Vyvgart use in gMG
- Swallowing issues highly common in MG patients: Study review